Clinical Trials at Colorado Blood Cancer Institute
As of August 2026, 58 paid clinical trials are recruiting at Colorado Blood Cancer Institute, located at 7535 E HAMPDEN AVE STE 400, DENVER, CO 80231-4844, phone (303) 276-4146 in Denver, Colorado. Active studies at this site cover conditions such as Breast Cancer, Multiple Myeloma and Advanced Solid Tumor. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
58 clinical trials at Colorado Blood Cancer Institute
·Clear filters·A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
DALY II USA/ MB-CART2019.1 for DLBCL
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
A Study of CTD402 in T-ALL/LBL Patients
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Common conditions studied in Denver
- Breast Cancer (18 active studies)
- Multiple Myeloma (17 active studies)
- Advanced Solid Tumor (15 active studies)
- Ovarian Cancer (11 active studies)
- Solid Tumor (11 active studies)
- Cystic Fibrosis (10 active studies)
Leading research sponsors in Denver
- University of Colorado, Denver
- Children's Oncology Group
- AstraZeneca
- National Cancer Institute (NCI)
- Eli Lilly and Company
Frequently asked questions
How many paid clinical trials are currently recruiting in Denver?
There are approximately 522 recruiting clinical trials in Denver, Colorado listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Denver pay participants?
Most recruiting trials in Denver compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Denver?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Denver?
The most common conditions under active study in Denver include Breast Cancer (18), Multiple Myeloma (17), Advanced Solid Tumor (15), Ovarian Cancer (11), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Denver?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Denver on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Denver?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Denver?
Recruiting research sites in Denver include Colorado Blood Cancer Institute, National Jewish Health, Sarah Cannon Research Institute at HealthONE, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Denver right now?
The largest active categories in Denver are Cancer & tumors (223), Cardiovascular (15), Diabetes & metabolic (10). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Colorado Blood Cancer Institute?
Colorado Blood Cancer Institute is located at 7535 E HAMPDEN AVE STE 400, DENVER, CO 80231-4844. Use the Google Maps link in the intro above to get directions.
How do I contact Colorado Blood Cancer Institute?
You can reach Colorado Blood Cancer Institute by phone at (303) 276-4146. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.